专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20110046155A1 HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 有权
标题翻译：盐酸衍生物作为HSP90的抑制剂
公开(公告)号：US20110046155A1
公开(公告)日：2011-02-24
申请号：US12445130
申请日：2007-10-12
申请人： Martyn Frederickson , John Francis Lyons , Neil Thomas Thompson , Mladen Vinkovic , Brian John Williams , Marian Williams , Andrew James Woodhead , Alison Jo-Anne Woolford
发明人： Martyn Frederickson , John Francis Lyons , Neil Thomas Thompson , Mladen Vinkovic , Brian John Williams , Marian Williams , Andrew James Woodhead , Alison Jo-Anne Woolford
IPC分类号： A61K31/497 , C07D403/06 , A61P35/00 , A61P31/10 , A61P33/02 , A61P25/00 , A61P31/12
CPC分类号： C07C67/317 , C07C59/08 , C07C67/313 , C07C69/92 , C07C235/60 , C07D209/44
摘要： The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analogue.
摘要翻译：本发明提供式（1）化合物的酸加成盐本发明还提供了制备式（1）化合物及其烷基类似物的方法，用于该方法的新中间体和制备中间体的方法。本发明还提供式（1）化合物及其乙基类似物的新的医学用途。

22. 发明授权

US09018214B2 Bicyclic heterocycle compounds and their uses in therapy 有权
标题翻译：双环杂环化合物及其在治疗中的应用
公开(公告)号：US09018214B2
公开(公告)日：2015-04-28
申请号：US14112597
申请日：2012-04-20
申请人： Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
发明人： Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
IPC分类号： A61K31/497 , A61K31/501 , C07D403/04 , C07D419/00 , C07D403/14 , C07D401/06 , C07D471/04 , C07D471/10 , C07D403/06 , C07D487/10
CPC分类号： C07D471/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , C07D401/06 , C07D403/06 , C07D403/14 , C07D413/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D519/00
摘要： The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
摘要翻译：本发明涉及式（I）的双环杂环化合物：或互变异构体或立体化学异构形式，N-氧化物，药学上可接受的盐或其溶剂合物; 其中R1，R2a，R2b，R3a，R3b，R5，R6，R7，R8，R9，p和E如本文所定义; 包含所述化合物的药物组合物和所述化合物在治疗疾病中的用途。癌症。

23. 发明申请

US20140179666A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY 有权
标题翻译：双相异构体化合物及其在治疗中的用途
公开(公告)号：US20140179666A1
公开(公告)日：2014-06-26
申请号：US14112597
申请日：2012-04-20
申请人： Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
发明人： Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
IPC分类号： C07D471/04 , C07D403/14 , C07D487/10 , C07D403/06 , C07D471/10
CPC分类号： C07D471/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , C07D401/06 , C07D403/06 , C07D403/14 , C07D413/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D519/00
摘要： The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
摘要翻译：本发明涉及式（I）的双环杂环化合物：或互变异构体或立体化学异构形式，N-氧化物，药学上可接受的盐或其溶剂合物; 其中R1，R2a，R2b，R3a，R3b，R5，R6，R7，R8，R9，p和E如本文所定义; 包含所述化合物的药物组合物和所述化合物在治疗疾病中的用途。癌症。

24. 发明申请

US20100113551A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES 审中-公开
标题翻译：包含（S）-2-氨基-1-（4-氯苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇的组合物作为蛋白激酶的调节剂
公开(公告)号：US20100113551A1
公开(公告)日：2010-05-06
申请号：US12531013
申请日：2008-03-14
申请人： Steven John Woodhead , David Charles Rees , Martyn Frederickson , Kyla Merriom Grimshaw
发明人： Steven John Woodhead , David Charles Rees , Martyn Frederickson , Kyla Merriom Grimshaw
IPC分类号： A61K31/415 , C07D231/12 , C07C211/00 , C07C245/00 , C07D303/00
CPC分类号： A61K31/415 , C07C215/32 , C07C247/10 , C07C309/30 , C07D231/12 , A61K2300/00
摘要： The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates.
摘要翻译：本发明提供包含（S）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇的组合物，其中组合物基本上不含的（R）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇或该组合物含有（S）和（（S）对映异构体占优势。还提供了制备（S）2-氨基-1-（4-氯 - 苯基）-1- [4-（1H-吡唑-4-基） - 苯基] - 乙醇的方法，新工艺中间体和制备新工艺中间体的方法。

25. 发明申请

US20110098290A1 PHARMACEUTICAL COMPOUNDS 有权
标题翻译：药物化合物
公开(公告)号：US20110098290A1
公开(公告)日：2011-04-28
申请号：US12902658
申请日：2010-10-12
申请人： Brian John Williams , Marian Williams , Martyn Frederickson
发明人： Brian John Williams , Marian Williams , Martyn Frederickson
IPC分类号： A61K31/496 , C07D403/10 , C07D403/14 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D295/155 , C07D209/44
摘要： The invention provides a compound of the formula (1): or a salt, solvate, N-oxide or tautomer thereof; wherein either R1 is R1a and R2 is R2a; or R1 is R1b and R2 is R2b; provided that in each case at least one of R1 and R2 is other than hydrogen; R1a and R2a are the same or different and each is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl wherein the C1-4 alkyl is optionally substituted by C1-2 alkoxy; R1b and R2b are the same or different and are selected from hydrogen, C(O)NR4R5, C(O)R6 and C(O)OR6 where R6 is C1-4 alkyl, R4 and R5 are both C1-4 alkyl, or NR4R5 forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from O, N or S and oxidised forms of N and S, the heterocyclic ring being optionally substituted by one or two C1-4 alkyl groups and/or one or two oxo groups; and R3 is a group D: wherein the asterisk denotes the point of attachment to the isoindoline ring; but excluding acetic acid 5-acetoxy-4-isopropyl-2-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindole-2-carbonyl]-phenyl ester.
摘要翻译：本发明提供式（1）化合物或其盐，溶剂合物，N-氧化物或其互变异构体; 其中R1是R1a，R2是R2a; 或R1为R1b且R2为R2b; 条件是在每种情况下，R 1和R 2中的至少一个不是氢; R1a和R2a相同或不同，各自选自氢，C 1-4烷基，C 2-4烯基和C 2-4炔基，其中C 1-4烷基任选被C 1-2烷氧基取代; R1b和R2b相同或不同，并且选自氢，C（O）NR4R5，C（O）R6和C（O）OR6，其中R6是C1-4烷基，R4和R5都是C1-4烷基或 NR4R5形成任选地含有选自O，N或S的第二杂原子环成员和氧化形式的N和S的4至7元饱和杂环，杂环任选被一个或两个C 1-4烷基和/或一个或两个氧代基团; 并且R 3是基团D：其中星号表示与异二氢吲哚环的连接点; 但不包括乙酸5-乙酰氧基-4-异丙基-2- [5-（4-甲基 - 哌嗪-1-基甲基）-1,3-二氢 - 异吲哚-2-羰基] - 苯酯。

26. 发明授权

US08383619B2 Pharmaceutical compounds 有权
标题翻译：药物化合物
公开(公告)号：US08383619B2
公开(公告)日：2013-02-26
申请号：US12902658
申请日：2010-10-12
申请人： Martyn Frederickson , Marian Williams
发明人： Brian John Williams , Martyn Frederickson
IPC分类号： A61K31/5377 , A61K31/496 , C07D413/14 , C07D403/14 , C07D403/06
CPC分类号： C07D295/155 , C07D209/44
摘要： The invention provides a compound of the formula (1): or a salt, solvate, N-oxide or tautomer thereof; wherein either R1 is R1a and R2 is R2a; or R1 is R1b and R2 is R2b; provided that in each case at least one of R1 and R2 is other than hydrogen; R1a and R2a are the same or different and each is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl wherein the C1-4 alkyl is optionally substituted by C1-2 alkoxy; R1b and R2b are the same or different and are selected from hydrogen, C(O)NR4R5, C(O)R6 and C(O)OR6 where R6 is C1-4 alkyl, R4 and R5 are both C1-4 alkyl, or NR4R5 forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from O, N or S and oxidized forms of N and S, the heterocyclic ring being optionally substituted by one or two C1-4 alkyl groups and/or one or two oxo groups; and R3 is a group D: wherein the asterisk denotes the point of attachment to the isoindoline ring; but excluding acetic acid 5-acetoxy-4-isopropyl-2-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindole-2-carbonyl]-phenyl ester.
摘要翻译：本发明提供式（1）化合物或其盐，溶剂合物，N-氧化物或其互变异构体; 其中R1是R1a，R2是R2a; 或R1为R1b且R2为R2b; 条件是在每种情况下，R 1和R 2中的至少一个不是氢; R1a和R2a相同或不同，各自选自氢，C 1-4烷基，C 2-4烯基和C 2-4炔基，其中C 1-4烷基任选被C 1-2烷氧基取代; R1b和R2b相同或不同，并且选自氢，C（O）NR4R5，C（O）R6和C（O）OR6，其中R6是C1-4烷基，R4和R5都是C1-4烷基或 NR4R5形成任选地含有选自O，N或S的第二杂原子环成员和氧化形式的N和S的4至7元饱和杂环，杂环任选被一个或两个C 1-4烷基和/或一个或两个氧代基团; 并且R 3是基团D：其中星号表示与异二氢吲哚环的连接点; 但不包括乙酸5-乙酰氧基-4-异丙基-2- [5-（4-甲基 - 哌嗪-1-基甲基）-1,3-二氢 - 异吲哚-2-羰基] - 苯酯。

27. 发明申请

US20070259871A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 有权
标题翻译：羟基苯甲酰胺衍生物及其作为HSP90抑制剂的用途
公开(公告)号：US20070259871A1
公开(公告)日：2007-11-08
申请号：US11680830
申请日：2007-03-01
申请人： Gianni Chessari , Maria Carr , Miles Congreve , Robert Downham , Martyn Frederickson , Christopher Murray , Eva Navarro , Michael O'Brien , Theresa Phillips , Andrew Woodhead , Alison Woolford
发明人： Gianni Chessari , Maria Carr , Miles Congreve , Robert Downham , Martyn Frederickson , Christopher Murray , Eva Navarro , Michael O'Brien , Theresa Phillips , Andrew Woodhead , Alison Woolford
IPC分类号： A61K31/4035 , A61K31/47 , A61K31/496 , A61K31/5377 , A61P35/00 , C07D209/04 , C07D215/00 , C07D217/00 , C07D227/00 , C07D241/00 , C07D265/30 , C07D401/02 , C07D471/00
CPC分类号： C07D401/12 , C07C65/21 , C07D209/08 , C07D209/44 , C07D215/08 , C07D217/06 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D491/08 , C07D491/10
摘要： The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.
摘要翻译：本发明提供式（I）的化合物：或其盐，互变异构体，溶剂合物和N-氧化物; 其中R 1是羟基或氢; R 2是羟基; 甲氧基或氢; 条件是R 1和R 2中的至少一个是羟基; R 3选自氢; 卤素; 氰基; 任选取代的C 1-5烃基和任选取代的C 1-5 - 烃氧基; R 4选自氢; 其中n为0或1且R 7为任选取代的无环C 1 - （O）N - ， - -5个烃基或具有3〜7个环成员的单环碳环或杂环基; 卤素; 氰基; 羟基; 氨基; 和任选取代的单或二-C 1-5烃基 - 氨基; 或R 3和R 4一起形成5至7个环成员的单环碳环或杂环; 并且NR 5 R 6形成具有8至12个环成员的任选取代的双环杂环基，其中多达5个环成员是选自氧，氮和硫的杂原子。该化合物具有作为Hsp90抑制剂的活性。

28. 发明申请

US20050124620A1 Pharmaceutical compounds 审中-公开
标题翻译：药物化合物
公开(公告)号：US20050124620A1
公开(公告)日：2005-06-09
申请号：US10962085
申请日：2004-10-08
申请人： Martyn Frederickson , Adrian Gill , Alessandro Padova , Miles Congreve
发明人： Martyn Frederickson , Adrian Gill , Alessandro Padova , Miles Congreve
IPC分类号： A61K31/404 , C07D209/08 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D471/02 , C07D487/02 , A61K31/53 , A61K31/519
CPC分类号： C07D401/06 , A61K31/404 , C07D209/08 , C07D401/14 , C07D403/06 , C07D403/12 , Y02A50/411
摘要： Compounds are disclosed of the formula (I): in which U, T, V and W are each a nitrogen atom or carbon atom. When U, T, V or W is a carbon atom, it may be substituted. The compounds are inhibitors of p38 MAP kinase and are useful for treating inflammatory diseases such as arthritis. An example of such a compound is:
摘要翻译：公开了式（I）的化合物：其中U，T，V和W各自为氮原子或碳原子。当U，T，V或W为碳原子时，它可以被取代。这些化合物是p38 MAP激酶的抑制剂，可用于治疗炎性疾病如关节炎。这种化合物的一个例子是：

29. 发明申请

US20060063782A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors 审中-公开
标题翻译： 3-芳基甲氧基吡啶及其类似物作为p38映射激酶抑制剂
公开(公告)号：US20060063782A1
公开(公告)日：2006-03-23
申请号：US10519922
申请日：2003-07-03
申请人： Christopher Murray , Michael Hartshorn , Martyn Frederickson , Miles Congreve , Alessandro Padova , Steven Woodhead , Adrian Gill , Andrew Woodhead
发明人： Christopher Murray , Michael Hartshorn , Martyn Frederickson , Miles Congreve , Alessandro Padova , Steven Woodhead , Adrian Gill , Andrew Woodhead
IPC分类号： A61K31/4965 , C07D213/63 , A61K31/44
CPC分类号： C07D213/73 , C07D213/65 , C07D213/74 , C07D213/81 , C07D241/18 , C07D241/20 , C07D241/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/12 , C07D417/14 , C07D513/04
摘要： Compounds of the formula (I), wherein: —X═Y— is selected from —CR =CR — and —CR ═N—; R is selected from H, halo, NRR′, NHC(═O)R, NHC(═O)NRR′, NH2SO2R, and C(═O)NRR′; R and R (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R is selected from R , halo, NHR , C(═O)NHR , OR , SR , NHC(═O)R , NHC(═O)NHR , NHS(═O)R , wherein R is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.
摘要翻译：式（I）的化合物，其中：-X-Y-选自-CR 2 = CR 3 - 和-CR 2 -N-; R 1选自H，卤素，NRR'，NHC（-O）R，NHC（-O）NRR'，NH 2 SO 2 R和C（-O）NRR'; R 2和R 3（如果存在）独立地选自H，任选取代的C 1-7烷基，任选取代的C 5-20芳基，任选取代的C 3-20杂环基，卤素，氨基，酰胺基，羟基，醚，硫代，硫醚，酰氨基，脲基和磺氨基; R 4是任选取代的C 5-20芳基或C 5-20杂芳基; R 5选自R 5，卤素，NHR 5，C（O）NHR 5，OR 5，SR 5，NHC（-O） R 5，NHC（-O）NHR 5，NHS（-O）R 5，其中R 5'是H或C 1-3烷基（任选地被卤素，NH 2，OH ，SH）被公开用于治疗和治疗通过抑制p38 MAP激酶而改善的疾病。

30. 发明申请

US20070276026A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 有权
标题翻译：羟基苯甲酰胺衍生物及其作为HSP90抑制剂的用途
公开(公告)号：US20070276026A1
公开(公告)日：2007-11-29
申请号：US11680805
申请日：2007-03-01
申请人： Gianni Chessari , Miles Congreve , Martyn Frederickson , Christopher Murray , Eva Navarro , Alison Woolford
发明人： Gianni Chessari , Miles Congreve , Martyn Frederickson , Christopher Murray , Eva Navarro , Alison Woolford
IPC分类号： A61K31/40 , C07D209/00
CPC分类号： C07D401/12 , C07C65/21 , C07D209/08 , C07D209/44 , C07D215/08 , C07D217/06 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D491/08 , C07D491/10
摘要： The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof, wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.
摘要翻译：本发明提供式（I）化合物或其盐，互变异构体，溶剂合物和N-氧化物，其中R 1是羟基或氢; R 2是羟基; 甲氧基或氢; 条件是R 1和R 2中的至少一个是羟基; R 3选自氢; 卤素; 氰基; 任选取代的C 1-5烃基和任选取代的C 1-5 - 烃氧基; R 4选自氢; 其中n为0或1且R 7为任选取代的无环C 1 - （O）N - ， - -5个烃基或具有3〜7个环成员的单环碳环或杂环基; 卤素; 氰基; 羟基; 氨基; 和任选取代的单或二-C 1-5烃基 - 氨基; 或R 3和R 4一起形成5至7个环成员的单环碳环或杂环; 并且NR 5 R 6形成具有8至12个环成员的任选取代的双环杂环基，其中多达5个环成员是选自氧，氮和硫的杂原子。该化合物具有作为Hsp90抑制剂的活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式